Shattuck Labs (NASDAQ:STTK – Get Free Report) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Briefing.com reports.
Several other equities analysts have also commented on the company. Needham & Company LLC dropped their target price on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Shattuck Labs in a report on Wednesday, May 15th.
Shattuck Labs Stock Performance
STTK opened at $6.19 on Monday. The company has a market cap of $294.33 million, a price-to-earnings ratio of -3.21 and a beta of 1.85. Shattuck Labs has a one year low of $1.33 and a one year high of $11.76. The business’s fifty day moving average is $8.75 and its two-hundred day moving average is $8.31.
Shattuck Labs (NASDAQ:STTK – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. Shattuck Labs’s revenue for the quarter was up 2200.0% on a year-over-year basis. On average, analysts predict that Shattuck Labs will post -1.56 EPS for the current fiscal year.
Institutional Trading of Shattuck Labs
A number of institutional investors have recently modified their holdings of the company. Franklin Resources Inc. purchased a new position in Shattuck Labs in the fourth quarter valued at about $11,663,000. Monashee Investment Management LLC acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $713,000. Tower Research Capital LLC TRC grew its position in Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after acquiring an additional 5,989 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Shattuck Labs during the fourth quarter valued at approximately $268,000. Finally, Reliant Investment Management LLC acquired a new position in shares of Shattuck Labs during the fourth quarter worth $143,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.
About Shattuck Labs
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.